Recursion Pharmaceuticals announced today that it has captured its first Utah Innovation Award, in the Life Sciences – BioTech category, for its Computationally Intelligent Discovery Engine. The Recursion engine combines experimental biology, automation and artificial intelligence to perform massively parallel drug screens using human cells, discovering treatments more efficiently than ever before.
“It is an honor to be recognized for the outstanding work of the Recursion Team,” said Chris Gibson, co-founder and CEO of Recursion Pharmaceuticals. “We are advancing our discovery platform and moving closer to our goal of discovering 100 treatments by the year 2025. Our success to date is a direct result of the incredible team we are building here at the foot of the Wasatch, and my hat is off to the team on this well-deserved win.”
Twenty-four innovations, and the Utah companies that created them, were named finalists or honorable mention recipients. Eight companies were named as winners in the 15th annual Utah Innovation Awards, presented by Stoel Rives LLP and the Utah Technology Council.
This statewide program is designed to recognize innovations that are making a significant impact in their industry. A committee of more than 80 experts from Utah’s private industry, government and academic communities voted on winners and finalists in each of the program’s eight categories: Clean Technology and Energy; Computer Hardware/Electrical Devices; Consumer Software; Enterprise Software, Cloud and Big Data; Life Science – Biotech; Life Science – Medical Device; Mechanical Systems/Chemicals/Manufacturing; and Outdoor and Consumer Products. The Selection Committee votes were tallied by accounting firm Grant Thornton.
“We are proud that our engine received this award alongside other outstanding Utah innovations.” said Gibson. “We look forward to expanding the Utah biotech industry as we extend our discovery engine into other areas of human cellular biology.”
Recursion Pharmaceuticals is an emerging biotechnology company based in Salt Lake City. Recursion combines experimental biology and bioinformatics with artificial intelligence in a massively parallel system to quickly and efficiently identify treatments for any disease which can be modeled at the cellular level. From its initial and continued focus on drug repurposing to treat rare diseases, Recursion has broadened its platform to probe rich data from high-throughput automated screens for a number of indications, including aging, inflammation, infectious disease, oncology, and diagnostics. Recursion’s ultimate vision is to leverage technology to build a robust and reliable map of human cellular biology, which would enable a radical shift in the pace and scale at which new treatments could benefit patients. Learn more at www.recursionpharma.com, or connect on Twitter, Facebook, and LinkedIn.